Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 8.59% is 31% below its 5-year average of 12.39%, near the low end of its 5-year range (8.59%–14.86%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.69% below its 12-month average of 9.52%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 8.59%.
RETURN ON EQUITY (ROE)
8.59%
RETURN ON EQUITY (ROE) AVG TTM
9.52%
RETURN ON EQUITY (ROE) AVG 3Y
11.46%
RETURN ON EQUITY (ROE) AVG 5Y
12.39%
RETURN ON EQUITY (ROE) AVG 10Y
13.47%
RETURN ON EQUITY (ROE) AVG 15Y
15.17%
RETURN ON EQUITY (ROE) AVG 20Y
16.14%
CURRENT VS TTM AVG
-9.69%
CURRENT VS 3Y AVG
-25.01%
CURRENT VS 5Y AVG
-30.63%
CURRENT VS 10Y AVG
-36.21%
CURRENT VS 15Y AVG
-43.37%
CURRENT VS 20Y AVG
-46.75%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+120.45%
vs the sector median at left
Utah Medical Products, Inc.
Market Cap
$235.08M
Return on Equity (ROE)
8.59%
TTM Avg
9.52%
3Y Avg
11.46%
5Y Avg
12.39%
Market Cap
$235.66M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
Market Cap
$235.97M
Return on Equity (ROE)
-1.67%
TTM Avg
19.58%
3Y Avg
23.42%
5Y Avg
29.49%
Market Cap
$236.82M
Return on Equity (ROE)
-25.20%
TTM Avg
-25.82%
3Y Avg
5.12%
5Y Avg
5.12%
Market Cap
$232.72M
Return on Equity (ROE)
-27.27%
TTM Avg
-92.43%
3Y Avg
-64.95%
5Y Avg
-57.80%
Market Cap
$237.57M
Return on Equity (ROE)
-59.27%
TTM Avg
-136.66%
3Y Avg
-113.26%
5Y Avg
-53.68%
Market Cap
$231.77M
Return on Equity (ROE)
-695.56%
TTM Avg
-3698.55%
3Y Avg
-1897.26%
5Y Avg
-1268.80%
Market Cap
$231.37M
Return on Equity (ROE)
-34.04%
TTM Avg
-95.97%
3Y Avg
-70.55%
5Y Avg
-68.40%
Market Cap
$239.01M
Return on Equity (ROE)
-31.55%
TTM Avg
-30.05%
3Y Avg
-33.97%
5Y Avg
-37.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Utah Medical Products, Inc. (UTMD) | $235.08M | 8.59% | 9.52% | 11.46% | 12.39% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | -118.58% | 62.37% | -376.78% | -340.60% |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | -1.67% | 19.58% | 23.42% | 29.49% |
| BioAge Labs Inc. (BIOA)vs › | $236.82M | -25.20% | -25.82% | 5.12% | 5.12% |
| InflaRx N.V. (IFRX)vs › | $232.72M | -27.27% | -92.43% | -64.95% | -57.80% |
| Invivyd, Inc. (IVVD)vs › | $237.57M | -59.27% | -136.66% | -113.26% | -53.68% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | -34.04% | -95.97% | -70.55% | -68.40% |
| High Tide Inc. (HITI)vs › | $239.01M | -31.55% | -30.05% | -33.97% | -37.95% |
| Century Therapeutics, Inc. (IPSC)vs › | $239.02M | -47.25% | -42.23% | -50.43% | -29.25% |
ROE
8.6%
ROA
8.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 8.59% |
| 2026-03-31 | 9.01% |
| 2025-12-31 | 9.46% |
| 2025-09-30 | 9.83% |
| 2025-06-30 | 10.68% |
| 2025-03-31 | 11.07% |
| 2024-12-31 | 11.81% |
| 2024-09-30 | 12.29% |
| 2024-06-30 | 12.60% |
| 2024-03-31 | 12.82% |
| 2023-12-31 | 12.96% |
| 2023-09-30 | 13.67% |
| 2023-06-30 | 14.17% |
| 2023-03-31 | 14.53% |
| 2022-12-31 | 14.42% |
| 2022-09-30 | 14.83% |
| 2022-06-30 | 14.86% |
| 2022-03-31 | 14.01% |
| 2021-12-31 | 13.80% |
| 2021-09-30 | 12.79% |
| 2021-06-30 | 11.92% |
| 2021-03-31 | 10.18% |
| 2020-12-31 | 10.50% |
| 2020-09-30 | 11.93% |
| 2020-06-30 | 13.13% |
| 2020-03-31 | 15.60% |
| 2019-12-31 | 14.57% |
| 2019-09-30 | 14.49% |
| 2019-06-30 | 17.91% |
| 2019-03-31 | 19.10% |
| 2018-12-31 | 20.85% |
| 2018-09-30 | 14.23% |
| 2018-06-30 | 11.40% |
| 2018-03-31 | 10.96% |
| 2017-12-31 | 10.89% |
| 2017-09-30 | 16.93% |
| 2017-06-30 | 16.90% |
| 2017-03-31 | 17.16% |
| 2016-12-31 | 17.51% |
| 2016-09-30 | 17.37% |
| 2016-06-30 | 17.92% |
| 2016-03-31 | 17.29% |
| 2015-12-31 | 17.00% |
| 2015-09-30 | 17.02% |
| 2015-06-30 | 16.73% |
| 2015-03-31 | 17.74% |
| 2014-12-31 | 17.63% |
| 2014-09-30 | 18.45% |
| 2014-06-30 | 17.85% |
| 2014-03-31 | 18.10% |
| 2013-12-31 | 18.83% |
| 2013-09-30 | 17.87% |
| 2013-06-30 | 19.66% |
| 2013-03-31 | 19.95% |
| 2012-12-31 | 19.95% |
| 2012-09-30 | 20.06% |
| 2012-06-30 | 20.39% |
| 2012-03-31 | 19.91% |
| 2011-12-31 | 18.19% |
| 2011-09-30 | 17.50% |
| 2011-06-30 | 15.85% |
| 2011-03-31 | 15.17% |
| 2010-12-31 | 15.92% |
| 2010-09-30 | 15.22% |
| 2010-06-30 | 15.79% |
| 2010-03-31 | 15.96% |
| 2009-12-31 | 16.48% |
| 2009-09-30 | 16.86% |
| 2009-06-30 | 17.94% |
| 2009-03-31 | 19.51% |
| 2008-12-31 | 20.70% |
| 2008-09-30 | 18.92% |
| 2008-06-30 | 19.67% |
| 2008-03-31 | 20.11% |
| 2007-12-31 | 20.38% |
| 2007-09-30 | 20.99% |
| 2007-06-30 | 21.48% |
| 2007-03-31 | 21.95% |
| 2006-12-31 | 22.62% |
| 2006-09-30 | 22.82% |
| 2006-06-30 | 22.97% |
| 2006-03-31 | 22.47% |
| 2005-12-31 | 22.97% |
| 2005-09-30 | 21.00% |
| 2005-06-30 | 21.04% |
| 2005-03-31 | 19.44% |
| 2004-12-31 | 28.27% |
| 2004-09-30 | 61.55% |
| 2004-06-30 | 59.13% |
| 2004-03-31 | 61.72% |
| 2003-12-31 | 56.83% |
| 2003-09-30 | 32.58% |
| 2003-06-30 | 36.61% |
